67 CENTS WASNT REAL
If you are not in RAFA this pullback retesting support is an opportunity
double digits this year coming
[h=1]Rafarma Embarks on Aggressive Global Partnerships Plan[/h][h=2][/h][FONT="]https://www.globenewswire.com/news-...-on-Aggressive-Global-Partnerships-Plan.html#[FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT]Email [FONT="][/FONT]Print Friendly [FONT="][/FONT]Share
March 04, 2021 10:55 ET | Source: RAFARMA PHARMACEUTICALS INC
Nicosia, Cyprus, March 04, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC
RAFA) is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022. Given Rafarma’s current market position and the regulatory arena for the circulation of medicinal drugs in various countries, the strategies are to pursue aggressive promotion of the company's technologies and their implementation.
The optimal scenario for such promotion is the expansion of collaboration with developers and effective commercial partners in the world market. These collaboration should provide faster access to key global and regional markets for the company's products achieved by contracts for partnership and mutual distribution. Such collaboration will significantly reduce the costs of product promotion and accelerate projects to develop new medicinal drugs and technologies, and their distribution.
In pursuit of these strategies, Rafarma is actively involved in the process of establishing contractual partnerships with approximately 200 companies in various countries, to be finalized by the summer of 2022. These include the USA, the EU and the ASEAN countries, China, Japan, Singapore, South Africa and Russia. Contractual partnerships have already been finalized with several companies in China, Uzbekistan, Czech Republic, Singapore, Malaysia and Russia.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
[h=2]Related Articles[/h]
[/FONT]
If you are not in RAFA this pullback retesting support is an opportunity
double digits this year coming
[h=1]Rafarma Embarks on Aggressive Global Partnerships Plan[/h][h=2][/h][FONT="]https://www.globenewswire.com/news-...-on-Aggressive-Global-Partnerships-Plan.html#[FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT][FONT="][/FONT]Email [FONT="][/FONT]Print Friendly [FONT="][/FONT]Share
March 04, 2021 10:55 ET | Source: RAFARMA PHARMACEUTICALS INC
Nicosia, Cyprus, March 04, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC
RAFA) is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022. Given Rafarma’s current market position and the regulatory arena for the circulation of medicinal drugs in various countries, the strategies are to pursue aggressive promotion of the company's technologies and their implementation.The optimal scenario for such promotion is the expansion of collaboration with developers and effective commercial partners in the world market. These collaboration should provide faster access to key global and regional markets for the company's products achieved by contracts for partnership and mutual distribution. Such collaboration will significantly reduce the costs of product promotion and accelerate projects to develop new medicinal drugs and technologies, and their distribution.
In pursuit of these strategies, Rafarma is actively involved in the process of establishing contractual partnerships with approximately 200 companies in various countries, to be finalized by the summer of 2022. These include the USA, the EU and the ASEAN countries, China, Japan, Singapore, South Africa and Russia. Contractual partnerships have already been finalized with several companies in China, Uzbekistan, Czech Republic, Singapore, Malaysia and Russia.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
[h=2]Related Articles[/h]
[/FONT]
That would be a step in the right direction. It’s up 66% this morning...
I doubled my position is RAFA, not a whole lot, but better than nothing, I guess...
Yes, thanks for pointing that out Chop.
PRED is now trading back on the sheets , off the greys .
Hearing lots of rumors , including a big shakeup in managment . I think the chart will be very helpful to monitor their progress . Believe it or not , PRED has been beaten down for so long, the long term mvg avg ( designed to show long terms trends in the stock) is about to turn bullish
a few closes over 22.50 cents will give buyers more confidence PRED that worth buying and holding on to
something to monitor next week .
$PRED Back from the Dead Predictive Biotechhttps://linkedin.com/feed/update/urn:li:activity:6767484197373296640/…Predictive Biotech is hiring Account Managers and Sales Representatives! If you have experience and are interested in this opportunity or know someone who would be, reach out #PRED
PRED is now trading back on the sheets , off the greys .
Hearing lots of rumors , including a big shakeup in managment . I think the chart will be very helpful to monitor their progress . Believe it or not , PRED has been beaten down for so long, the long term mvg avg ( designed to show long terms trends in the stock) is about to turn bullish
a few closes over 22.50 cents will give buyers more confidence PRED that worth buying and holding on to
something to monitor next week .
$PRED Back from the Dead Predictive Biotechhttps://linkedin.com/feed/update/urn:li:activity:6767484197373296640/…Predictive Biotech is hiring Account Managers and Sales Representatives! If you have experience and are interested in this opportunity or know someone who would be, reach out #PRED
FROM SAA
Predictive Technology Group PRED .16
www.predtechgroup.com
Those of you that think PRED is dead- think again!!!
Update:
Application for new patent: https://docoh.com/patent/by/company...evw--E2IG4vxaO6CkQ6Mb4xD_-dCq8XapVLM8to1XH9tM
See updated info on PRED https://www.amidoctors.com/predicti...yhA5Tf0Ywyz3BfGjuM_T4iKmbb9otZc2VWWzf8ewALIOI
Finally got off the "Grey" market and currently trading with a number of market makers. A. See just release an article that mentions PRED
https://ksusentinel.com/2021/03/12/...el-corporation-atlas-medical-uk-babystart-ltd
Note; We know that this investment has been terrible for the past 1 1/2 years and the losses have been substantial. PRED in our opinion may be developing "green shoots" that will reward the extra patient investor near term! We anticipate that the "skull and Cross bones" will be removed shortly and that will dramatically enhance investor interest and participation. Believe it or not PRED breeds cutting edge technology, but the recent price debacle resulting from missteps,Covid and shorts all have contributed to the current share price. We remain confident that on the other side is a pasture of Unicorns. Lower ones cost structure we believe is the most prudent course of action especially @ .16.
Investors need to stop concentrating on the share price and consider the hidden value in PRED! They have a genetic library that contains some 300k DNA samples worth a lot of money! The tests for Endometriosis and Infertility were hampered by the Covid shutdown.
The Stem Cell market size was estimated to be worth $4.6 billion (2020) and is projected to grow to $8.8 billion by the end of 2025.
The growing medical burden can lead to a rise in population, which drives the stem cell market.
The increased patient base for target diseases such as cancer, Leukemia, cardiovascular disease, neuro-degenerative disorders, and gastrointestinal diseases elevate the growth of the North American stem cell market.
PRED during the past few months has filed an EUA with FDA concerning the usage of Stem Cells for severe respiratory symptoms related to Covid.
PRED recently introduced "Wharton Jelly Flow". The marketplace has been extremely receptive to this new product.
Please spend some time and review the biotech division of PRED!
https://www.predictivebiotech.com/products/
We remain committed and confident that PRED will start to perform for shareholders.
BTW , Expecting RAFA numbers this week, and all audits complete by the end of April
This should trigger its push for uplisting
Predictive Technology Group PRED .16
www.predtechgroup.com
Those of you that think PRED is dead- think again!!!
Update:
Application for new patent: https://docoh.com/patent/by/company...evw--E2IG4vxaO6CkQ6Mb4xD_-dCq8XapVLM8to1XH9tM
See updated info on PRED https://www.amidoctors.com/predicti...yhA5Tf0Ywyz3BfGjuM_T4iKmbb9otZc2VWWzf8ewALIOI
Finally got off the "Grey" market and currently trading with a number of market makers. A. See just release an article that mentions PRED
https://ksusentinel.com/2021/03/12/...el-corporation-atlas-medical-uk-babystart-ltd
Note; We know that this investment has been terrible for the past 1 1/2 years and the losses have been substantial. PRED in our opinion may be developing "green shoots" that will reward the extra patient investor near term! We anticipate that the "skull and Cross bones" will be removed shortly and that will dramatically enhance investor interest and participation. Believe it or not PRED breeds cutting edge technology, but the recent price debacle resulting from missteps,Covid and shorts all have contributed to the current share price. We remain confident that on the other side is a pasture of Unicorns. Lower ones cost structure we believe is the most prudent course of action especially @ .16.
Investors need to stop concentrating on the share price and consider the hidden value in PRED! They have a genetic library that contains some 300k DNA samples worth a lot of money! The tests for Endometriosis and Infertility were hampered by the Covid shutdown.
The Stem Cell market size was estimated to be worth $4.6 billion (2020) and is projected to grow to $8.8 billion by the end of 2025.
The growing medical burden can lead to a rise in population, which drives the stem cell market.
The increased patient base for target diseases such as cancer, Leukemia, cardiovascular disease, neuro-degenerative disorders, and gastrointestinal diseases elevate the growth of the North American stem cell market.
PRED during the past few months has filed an EUA with FDA concerning the usage of Stem Cells for severe respiratory symptoms related to Covid.
PRED recently introduced "Wharton Jelly Flow". The marketplace has been extremely receptive to this new product.
Please spend some time and review the biotech division of PRED!
https://www.predictivebiotech.com/products/
We remain committed and confident that PRED will start to perform for shareholders.
BTW , Expecting RAFA numbers this week, and all audits complete by the end of April
This should trigger its push for uplisting
looked alot better last week, hella of pop
PRED , strong rumor this should be removed from the stock this week
one baby step at time
OTC Markets Group designates certain securities as 'Caveat Emptor' and places a skull and crossbones icon next to the stock symbol to inform investors that there may be reason to exercise additional care and perform thorough due diligence before making an investment decision in that security.
